Friday, April 12, 2019, Anaheim, California, 12:15 PM – 1:45 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from Practice — A 6-Part CNE Symposia Series Held During the ONS 44th Annual Congress

PART 6 — Emerging Strategies in Non-Small Cell Lung Cancer

Location:
Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Hotel Phone: (714) 750-8000

Meeting Room:
Grand Ballroom E-K (Lobby Level)
Schedule:
11:45 AM – 12:15 PM
Registration and Lunch Buffet

12:15 PM – 1:45 PM
Educational Program
 
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.

Faculty:
Kelly EH Goodwin, MSN, RN, ANP-BC
Thoracic Cancer Center
Massachusetts General Hospital
Boston, Massachusetts

Joel W Neal, MD, PhD
Assistant Professor of Medicine
Division of Oncology
Stanford Cancer Institute
Stanford University
Stanford, California

Judy Pagtama, RN, MSN, FNP-C
Nurse Practitioner
Stanford Cancer Institute
Stanford, California

Anne S Tsao, MD
Professor
Director, Mesothelioma Program
Director, Thoracic Chemo-Radiation Program
Department of Thoracic/Head and Neck Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida
 
Meeting space has been assigned to provide a symposium supported by AstraZeneca Pharmaceuticals LP during the Oncology Nursing Society’s (ONS) 44th Annual Congress, April 11-14, 2019 in Anaheim, California. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
11:45 AM – 12:15 PM — Registration and Lunch Buffet
12:15 PM – 1:45 PM — Educational Program

Cases Presented Will Include Discussion of the Following Topics:

  • Available efficacy and safety data with osimertinib as first-line therapy for patients with non-small cell lung cancer (NSCLC) and an EGFR tumor mutation
  • Emergence of immune checkpoint inhibition as a therapeutic consideration for patients with locally advanced NSCLC
  • Role of anti-PD-1/PD-L1 antibodies in combination with chemotherapy and/or anti-angiogenic agents as first-line treatment for advanced NSCLC
A detailed agenda will be available in the coming weeks

Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.

Learning Objectives and Goals:
Upon completion of this activity, participants should be able to:

  • Review the recent FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III non-small cell lung cancer (NSCLC) who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and discern how this strategy can be appropriately and safely integrated into routine clinical practice.
  • Review recent FDA approvals and other therapeutic advances related to the long-term management of metastatic NSCLC with an EGFR tumor mutation, and discern how this information should be applied to current off-protocol patient care.
  • Appreciate available clinical trial data with and the current role of anti-PD-1/PD-L1 antibodies in combination with chemotherapy and/or anti-angiogenic agents as first-line therapy for patients with metastatic NSCLC.
  • Educate patients about the side effects associated with recently approved therapies for NSCLC, and provide preventive strategies to reduce or ameliorate these toxicities.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with NSCLC to optimize clinical and quality of-life outcomes.
Accreditation Statement:
Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements:
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information:
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures:
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP CME/CNE planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Supporters:
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Hotel Phone: (714) 750-8000

Meeting Room: 
Grand Ballroom E-K (Lobby Level)

The Anaheim Marriott is the headquarters hotel for the 2019 ONS Congress and is conveniently located near the Anaheim Convention Center (0.2 miles).

 

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.

There is no registration fee for this event. However, preregistration is highly recommended as seating is limited.

Registration for clinicians in practice

• I am a practicing nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Standby registration for nonclinicians/industry professionals*

For all other professionals, we are unable to confirm seating at this time. If you would like to stand by for participation in this event, please provide your contact information. Should seats become available for the program, we will notify you.

Standby registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CNE programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.